Trial Profile
A Non-interventional Study of Carfilzomib (Kyprolis®) in Combination With Lenalidomide (Revlimid®) and Dexamethasone or Carfilzomib in Combination With Dexamethasone Alone or Carfilzomib in Combination With Daratumumab (Darzalex®) and Dexamethasone in Patients With Multiple Myeloma Who Have Received at Least One Prior Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms CARO
- 07 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 02 Jun 2022 Planned End Date changed from 30 Sep 2024 to 30 Jun 2025.
- 02 Jun 2022 Planned primary completion date changed from 30 Sep 2024 to 30 Jun 2025.